<DOC>
	<DOCNO>NCT01162486</DOCNO>
	<brief_summary>The aim study evaluate ( 1 ) safety tolerability escalate dos rifapentine ( RPT ) administer daily oral ; ( 2 ) effect increase dos RPT cytochrome P450 isoform 3A ( CYP3A ) enzyme metabolize activity , use single-dose midazolam ( MDZ ) ; ( 3 ) effect increase dos RPT autoinduction RPT metabolism .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Escalating Rifapentine Doses Healthy Volunteers</brief_title>
	<detailed_description>On day 1 , volunteer receive single dose MDZ dose 15 mg deliver orally , 24-hour PK analysis MDZ metabolite , 1-OH-midazolam ( 1-OH-MDZ ) perform . RPT ( RIF ) give single daily dose ( 5 , 10 , 15 , 20 mg/kg , depend dose cohort ) day 2-15 ( 14 dos ) . A 24-hour PK analysis RPT ( RIF ) 25-deacetyl metabolite ( 25-des-RPT ) perform first dose ( day 2 ) . On day 15 , volunteer receive second single dose MDZ . A 72-hour RPT ( RIF ) 24-hour MDZ ( 1-OH-MDZ ) PK analysis perform second dose MDZ begin day 15 . The PK sample occur in-patient basis General Clinical Research Center ( GCRC ) out-patient basis study clinic . Volunteers undergo assessment adverse event ( AEs ) several time throughout study . Each dose cohort contain 6 subject . RPT dose begin 5 mg/kg ( 6 volunteer ) increase 5 mg/kg increment ( 6 volunteer 10 , 15 , 20 mg/kg ) maximum dose 20 mg/kg unless dose-limiting toxicity ( DLT ) see two patient within dose cohort , case dose 2.5 mg/kg lower previous dose enrol determine maximal tolerate dose ( MTD ) . In addition , one cohort 6 subject receive RIF 10 mg/kg daily , rather RPT , comparator arm .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1 . Ability willingness provide write informed consent . 2 . Age great equal 18 year , less equal 65 year . 3 . Weight 50100 kg enrollment RPT cohorts 4 . Weight 5080 kg enrollment RIF cohort 5 . Within 28 few day prior enrollment , complete blood count differential , comprehensive serum chemistry profile , HIV antibody test , Hepatitis C antibody test perform , follow laboratory value : 1 . Serum amino aspartate transferase ( AST ) less upper limit normal 2 . Total bilirubin level less upper limit normal 3 . Serum creatinine &lt; 1.5 mg/dL 4 . Hemoglobin great 12.0 men , great 11.0 woman 5 . Platelet count great equal 125,000 /cu mm 6 . Absolute neutrophil count great equal 1250 /cu mm 7 . Serum albumin great 3.5 g/dL 8 . HIV antibody test negative 9 . Hepatitis C antibody negative 6 . For woman childbearing potential , negative serum bHCG pregnancy test , perform screening . 7 . During study 14 day last dose study medication , woman childbearing potential must agree practice barrier contraception duration study . 1 . Pregnant breastfeed 2 . Known intolerance allergy rifamycins 3 . Allergy benzodiazepines 4 . Use rifamycin antibiotic 30 day prior enrollment 5 . Inability take oral medication 6 . Renal , hepatic , cardiac ( except benign heart murmur ) , endocrine disorder ; malignancy ; immunocompromise . 7 . History acute chronic illness require current medical therapy . 8 . Prior gastrointestinal surgery involve stomach , biliary system , pancreas , small intestine . 9 . Any medical condition , opinion investigator , would interfere subject 's ability participate protocol . 10 . Any illicit drug use within precede 2 month . Subjects must agree abstain alcohol illicit drug use study . Smokers must agree abstain cigarette smoke few 5 cigarette per day . 11 . Current use prescription medication ( ) , include oral contraceptive . 12 . Planned use , study Day 0 last PK blood draw , follow : prescription medication ( ) , herbal supplement ( ) , vitamin ( ) , mineral supplement ( ) , overthecounter medication ( ) , grapefruit juice . Subjects must agree abstain grapefruit juice study . 13 . Participation investigational drug study within 30 day prior study entry study . 14 . Inability participate pharmacokinetic visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Anti-infective agent</keyword>
	<keyword>Anti-bacterial agent</keyword>
	<keyword>Rifampin</keyword>
	<keyword>Rifapentine</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Molecular mechanism pharmacological action</keyword>
	<keyword>Antitubercular agent</keyword>
	<keyword>Pharmacologic action</keyword>
</DOC>